Polymers for Solubility Enhancement Will Drive the Oral Solid Dosage Forms Market
Poor solubility has been a major challenge in the formulation development for oral solid dosage form (OSDF) pharmaceuticals, a preferred route for pharmaceutical consumption. Various methods have been researched to improve solubility of poorly soluble APIs and among these the use of polymers for solubility enhancement in solid dispersions is among the most popular.
Identifying the importance of the trend and to fulfil inadequately assessed market for polymers for solubility enhancement, global consulting and research firm Kline & Company is announcing the undertaking of a comprehensive study on Polymers for Solubility Enhancement in Pharmaceutical Oral Solid Dosage Forms: Global Market Analysis and Opportunities. The study will cover current and forecast demand by major products, supplier sales, and technical and market trends, as well as market opportunities and challenges for manufacturers of these polymers worldwide.
Oral administration is a natural means of consumption and is best for chronic drug therapy. In addition, the manufacturing of OSDF can be an advantage compared to other dosage forms; positively impacting the price of pharmaceutical products.
Nikola Matic, Industry Manager at Kline's Chemicals & Materials practice, states: “After having pushed in the direction of OSDFs for many years, the pharmaceutical industry now faces a dilemma stemming from the poor solubility of an increasing number of new drugs. Furthermore, of about 80–90% of products in the R&D pipeline are reported to be poorly soluble in water. As a result, this triggers low oral bioavailability and could in turn jeopardize the development of new drugs.”
Solubility is growing in importance and those who are able to capitalize on the potential that these enhancers bring to the table will see its inherent value. “Solubility enhancement is becoming a must for pharmaceutical companies and an area representing vast growth potential for chemical suppliers since tomorrow’s block-busters will most likely make use of one of the possible technologies to increase dissolution rate,” adds Matic.
This is a complex topic and today’s reality can quickly evolve into something different tomorrow as the industry experiences trends and innovations that influence its course. Kline’s Polymers for Solubility Enhancement in Pharmaceutical Oral Solid Dosage Forms: Global Market Analysis and Opportunities report will introduce all available technology and present their advantages and/or constraints and will focus on the polymers available for solubility enhancement through solid dispersion. The report will provide insights into the global market and regional specificities for solubility enhancement and provide a comprehensive overview of the markets’ present undertakings, and, most importantly, shed light on what lies ahead in the unknown future.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.